Citigroup’s NovoCure NVCR Stock Holding History

Citigroup’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-75,900	Closed	-$1.13M	–	5790
2023 Q4	$1.13M	Hold	75,900	–	–	﹤0.01%	2718
2023 Q3	$1.23M	Hold	75,900	–	–	﹤0.01%	2347
2023 Q2	$3.15M	Buy	75,900 +69,500	+1,086%	+$4.32M	﹤0.01%	1821
2023 Q1	$385K	Sell	6,400 -150,000	-96%	-$12M	﹤0.01%	3311
2022 Q4	$11.5M	Sell	156,400 -43,600	-22%	-$3.28M	0.01%	1060
2022 Q3	$15.2M	Buy	200,000 +50,000	+33%	+$3.9M	0.01%	928
2022 Q2	$10.4M	Hold	150,000	–	–	0.01%	1137
2022 Q1	$12.4M	Sell	150,000 -230,000	-61%	-$16.9M	0.01%	1183
2021 Q4	$28.5M	Buy	380,000 +5,000	+1%	+$502K	0.02%	831
2021 Q3	$43.6M	Buy	375,000 +25,000	+7%	+$3.78M	0.03%	593
2021 Q2	$77.6M	Buy	+350,000	New	+$68.1M	0.05%	373
2017 Q4	–	Sell	-11,500	Closed	-$228K	–	7620
2017 Q3	$228K	Buy	+11,500	New	+$226K	﹤0.01%	4883

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Citigroup's NVCR Position: Q2 2026 in Review

Citigroup increased its NovoCure (NVCR) stake by 203% in Q2 2026, buying an estimated $4.21M and bringing the position to 415,517 shares worth $6.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1952.

Citigroup first reported a position in NVCR in Q4 2015 and has held it in 43 quarters since. The position peaked at $23.8M in Q4 2020. 218 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

Citigroup held 415,517 shares of NovoCure worth $6.3M as of Q2 2026.
Citigroup bought 278,507 NovoCure shares in Q2 2026, an estimated $4.21M.
NovoCure made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #1952 holding.
Citigroup first reported a position in NovoCure in Q4 2015 and has held it in 43 quarters since.
Citigroup's NovoCure position peaked at $23.8M in Q4 2020.
218 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.